Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€61.00

€61.00

-2.560%
-1.6
-2.560%
€80.00

€80.00

 
Latest predictions
-
08.02.21
buy
€80.00
07.02.21
buy
€80.00
18.01.21
buy
-
11.01.21
buy
-
13.12.20
buy
-
12.12.20
buy
Your prediction

Formycon AG Stock

A loss of -2.560% shows a downward development for Formycon AG.
We see a rather positive sentiment for Formycon AG with 8 Buy predictions and 1 Sell predictions.
With a target price of €80.00 there is a positive potential of 31.148% for Formycon AG compared to the current price of €61.00.
Our community identified positive and negative aspects for Formycon AG stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Formycon AG stock. On the other hand our users think that "General Risks" could be a problem in the future.

Pros and Cons of Formycon AG in the next few years

Pros
3
Could be worthwhile Investment >10% per year
1
Differentiated customer and product portfolio
1
Small cyclical dependencies
Cons
1
Higher risks for its business
1
Low dividend yield expected
1
High valuation

Performance of Formycon AG vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Formycon AG -2.560% -6.006% 1.623% 151.406% 18.113% 101.610% 174.899%
Biofrontera AG -1.920% -3.512% -19.444% -41.935% -12.709% -51.667% 19.287%
Paion AG 0.900% -4.701% -10.442% 0.905% -7.083% -7.277% -7.238%
MagForce AG 0.920% -4.595% -4.176% 21.788% -13.492% -35.693% -12.748%

Other discussions about Formycon AG Stock

New thread Forum

News

DGAP-News: Chief Operating Officer Dr. Stefan Glombitza appointed to Formycon AG's Management Board for another Four Years
DGAP-News: Chief Operating Officer Dr. Stefan Glombitza appointed to Formycon AG's Management Board for another Four Years
DGAP-News: Formycon Reports its Nine-month Figures for 2020
DGAP-News: Formycon Reports its Nine-month Figures for 2020
DGAP-News: Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)
DGAP-News: Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)